[
  {
    "ts": null,
    "headline": "Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound",
    "summary": "Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.  Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound.  Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year.",
    "url": "https://finnhub.io/api/news?id=eb06a1a9150807d1dc15d9e0dd1074294225af40555650eaa069253aa27b7293",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733437586,
      "headline": "Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound",
      "id": 131805389,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.  Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound.  Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year.",
      "url": "https://finnhub.io/api/news?id=eb06a1a9150807d1dc15d9e0dd1074294225af40555650eaa069253aa27b7293"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments",
    "summary": "Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet growing demand for its diabetes and weight-loss medicines.",
    "url": "https://finnhub.io/api/news?id=b54df05038b979c70c8614b5000f4a4c2645ec223aefc74ffc1dc650cf46a52d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733432640,
      "headline": "Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments",
      "id": 131802729,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet growing demand for its diabetes and weight-loss medicines.",
      "url": "https://finnhub.io/api/news?id=b54df05038b979c70c8614b5000f4a4c2645ec223aefc74ffc1dc650cf46a52d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
    "summary": "Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care",
    "url": "https://finnhub.io/api/news?id=ffd1873da90a0551b54a42838e1cc063735128e8cd5a68ba34bd8a3a93662710",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733431798,
      "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
      "id": 131802730,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care",
      "url": "https://finnhub.io/api/news?id=ffd1873da90a0551b54a42838e1cc063735128e8cd5a68ba34bd8a3a93662710"
    }
  },
  {
    "ts": null,
    "headline": "Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars",
    "summary": "Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.  The new investment in the factory, which it acquired from Nexus Pharmaceuticals, will help boost production of Lilly's powerful weight-loss drug Zepbound as well as its diabetes treatments and other medicines, the company said.  “Today's announcement represents our single largest U.S. manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines,” said Edgardo Hernandez, Lilly's president of global manufacturing.",
    "url": "https://finnhub.io/api/news?id=c6c902caa6a342b5cd9d78f08617a529219910ad4281ba6fe3dd432313fc282a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733431218,
      "headline": "Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars",
      "id": 131802731,
      "image": "https://media.zenfs.com/en/reuters-finance.com/5c6d00e89fe1de842f55593a089bdd83",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.  The new investment in the factory, which it acquired from Nexus Pharmaceuticals, will help boost production of Lilly's powerful weight-loss drug Zepbound as well as its diabetes treatments and other medicines, the company said.  “Today's announcement represents our single largest U.S. manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines,” said Edgardo Hernandez, Lilly's president of global manufacturing.",
      "url": "https://finnhub.io/api/news?id=c6c902caa6a342b5cd9d78f08617a529219910ad4281ba6fe3dd432313fc282a"
    }
  },
  {
    "ts": null,
    "headline": "Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.",
    "url": "https://finnhub.io/api/news?id=07b8820fb36fc8bfab3a5c79ad3f1b4370d2ed77cd9207100e547234d5eb7a9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733430600,
      "headline": "Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin",
      "id": 131802732,
      "image": "https://media.zenfs.com/en/prnewswire.com/042b1e067c5a8c66fa3ca46f37a820f2",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.",
      "url": "https://finnhub.io/api/news?id=07b8820fb36fc8bfab3a5c79ad3f1b4370d2ed77cd9207100e547234d5eb7a9e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs",
    "summary": "Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs",
    "url": "https://finnhub.io/api/news?id=c5a6d1e862f6d65f315e5f81788afcc364e4de483151473c4be9f94856bd3d35",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733427600,
      "headline": "Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs",
      "id": 131873838,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly invests $3 billion to expand Wisconsin factory to help meet demand for blockbuster drugs",
      "url": "https://finnhub.io/api/news?id=c5a6d1e862f6d65f315e5f81788afcc364e4de483151473c4be9f94856bd3d35"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments -- Update",
    "summary": "By Sabela Ojea Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker...",
    "url": "https://finnhub.io/api/news?id=2bce532ec215ca4a59403a4cdced2df49677252f0e5c4d253b6e032d04de1d1d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733420708,
      "headline": "Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments -- Update",
      "id": 131803718,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker...",
      "url": "https://finnhub.io/api/news?id=2bce532ec215ca4a59403a4cdced2df49677252f0e5c4d253b6e032d04de1d1d"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Declines as Biotech Gives Back Some Gains - Health Care Roundup",
    "summary": "Health-care companies fell amid trepidation ahead of the jobs report weighed on high-risk stock-market niches, including biotechnology. Eli Lilly said it would invest $3 billion to expand a...",
    "url": "https://finnhub.io/api/news?id=753b4d99c8855e3612019d6837c9f6facea099f82ae5b71dc47da6576446753c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733419210,
      "headline": "Health Care Declines as Biotech Gives Back Some Gains - Health Care Roundup",
      "id": 131803004,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Health-care companies fell amid trepidation ahead of the jobs report weighed on high-risk stock-market niches, including biotechnology. Eli Lilly said it would invest $3 billion to expand a...",
      "url": "https://finnhub.io/api/news?id=753b4d99c8855e3612019d6837c9f6facea099f82ae5b71dc47da6576446753c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=2020fa78922edcd71244fe2c4a5be54da06953c4e65528f94231906389d882ba",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733416380,
      "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "id": 131873839,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=2020fa78922edcd71244fe2c4a5be54da06953c4e65528f94231906389d882ba"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Mounjaro to Be Rolled Out Initially to High-Need Obesity Patients in England",
    "summary": "Eli Lilly's (LLY) weight loss drug Mounjaro, or tirzepatide, will be rolled out initially to people",
    "url": "https://finnhub.io/api/news?id=12f3095a7d81e6fe24cda41b36e4adac50ac260c09e1910acbc93246fb588a74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733414488,
      "headline": "Eli Lilly's Mounjaro to Be Rolled Out Initially to High-Need Obesity Patients in England",
      "id": 131802733,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's (LLY) weight loss drug Mounjaro, or tirzepatide, will be rolled out initially to people",
      "url": "https://finnhub.io/api/news?id=12f3095a7d81e6fe24cda41b36e4adac50ac260c09e1910acbc93246fb588a74"
    }
  },
  {
    "ts": null,
    "headline": "The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials",
    "summary": "Eli Lilly's weight loss drug Zepbound proves superior in clinical trials",
    "url": "https://finnhub.io/api/news?id=8181f864b2ebab8fec2e12af53ab1c670f2016dc39522695cac5e5133d2fd79c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733407810,
      "headline": "The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials",
      "id": 131792042,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's weight loss drug Zepbound proves superior in clinical trials",
      "url": "https://finnhub.io/api/news?id=8181f864b2ebab8fec2e12af53ab1c670f2016dc39522695cac5e5133d2fd79c"
    }
  },
  {
    "ts": null,
    "headline": "The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market",
    "summary": "An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=94422373500cce03d9783f359e51c494f13d8332497dcb305ffcf29cd3d2bfed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733403625,
      "headline": "The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market",
      "id": 131792043,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=94422373500cce03d9783f359e51c494f13d8332497dcb305ffcf29cd3d2bfed"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly announces topline results from SURMOUNT-5 trial",
    "summary": "Eli Lilly (LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes",
    "url": "https://finnhub.io/api/news?id=e19e5e132952124bb8a67a34f7c843689e893ba704a071960e2e71b7a19555f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733400013,
      "headline": "Eli Lilly announces topline results from SURMOUNT-5 trial",
      "id": 131792045,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes",
      "url": "https://finnhub.io/api/news?id=e19e5e132952124bb8a67a34f7c843689e893ba704a071960e2e71b7a19555f6"
    }
  },
  {
    "ts": null,
    "headline": "Bitcoin Is Soaring for This Reason. Why Investors Should Beware the Crypto Rally and 5 Other Things to Know Today.",
    "summary": "Meta Platforms plans to build biggest-ever data center, Eli Lilly’s rivalry with Novo Nordisk Just ramped up, and more news to start your day.",
    "url": "https://finnhub.io/api/news?id=1e80cd94a37a5b3397da5500d0a146d0e5cf094634bb425d5510734a4e2cead0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733399520,
      "headline": "Bitcoin Is Soaring for This Reason. Why Investors Should Beware the Crypto Rally and 5 Other Things to Know Today.",
      "id": 131792046,
      "image": "https://s.yimg.com/ny/api/res/1.2/rEMGVpIldcOMVQ6Bfs44DQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/3232267dd8f7150d1d18fa54155512f9",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Meta Platforms plans to build biggest-ever data center, Eli Lilly’s rivalry with Novo Nordisk Just ramped up, and more news to start your day.",
      "url": "https://finnhub.io/api/news?id=1e80cd94a37a5b3397da5500d0a146d0e5cf094634bb425d5510734a4e2cead0"
    }
  },
  {
    "ts": null,
    "headline": "LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study",
    "summary": "LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.",
    "url": "https://finnhub.io/api/news?id=75ed3ed21f0f469dc436389f3039a55902d53008f1d85bc9d1700cc34e6a1c05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733398320,
      "headline": "LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study",
      "id": 131792048,
      "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.",
      "url": "https://finnhub.io/api/news?id=75ed3ed21f0f469dc436389f3039a55902d53008f1d85bc9d1700cc34e6a1c05"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly collaboration to accelerate biotech manufacturing",
    "summary": "Through a new agreement, Eli Lilly and Company and contract development and manufacturing organisation Cambrex will enable external biotech collaborators to accelerate their product development.Und...",
    "url": "https://finnhub.io/api/news?id=041f2820a4e920d39565af1432c2b93042c0e6d0a84344fa41aa1b4b5e3e004d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733396471,
      "headline": "Eli Lilly collaboration to accelerate biotech manufacturing",
      "id": 131793031,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Through a new agreement, Eli Lilly and Company and contract development and manufacturing organisation Cambrex will enable external biotech collaborators to accelerate their product development.Und...",
      "url": "https://finnhub.io/api/news?id=041f2820a4e920d39565af1432c2b93042c0e6d0a84344fa41aa1b4b5e3e004d"
    }
  },
  {
    "ts": null,
    "headline": "This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?",
    "summary": "Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.",
    "url": "https://finnhub.io/api/news?id=10cdfd3c399209a29cd918f0beacb3b8273005fd06e1f8673bf73de717a86b26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733394720,
      "headline": "This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?",
      "id": 131792049,
      "image": "https://g.foolcdn.com/editorial/images/799648/pharmacist-filling-a-prescription.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.",
      "url": "https://finnhub.io/api/news?id=10cdfd3c399209a29cd918f0beacb3b8273005fd06e1f8673bf73de717a86b26"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%",
    "summary": "INDIANAPOLIS - Eli Lilly and Company today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.Zepbound provided a 47% greater relative weight loss compared...",
    "url": "https://finnhub.io/api/news?id=e261ef3d93989c03dedfed756306dee90d5e5a261ea97651da17cef1bcd35c7d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733392723,
      "headline": "Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%",
      "id": 131792144,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.Zepbound provided a 47% greater relative weight loss compared...",
      "url": "https://finnhub.io/api/news?id=e261ef3d93989c03dedfed756306dee90d5e5a261ea97651da17cef1bcd35c7d"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.",
    "summary": "Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.",
    "url": "https://finnhub.io/api/news?id=ff32eb3015495fec0a7873e070a37693202fd43522229d44f1816bcd96a8a0a7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733371200,
      "headline": "Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.",
      "id": 131873841,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.",
      "url": "https://finnhub.io/api/news?id=ff32eb3015495fec0a7873e070a37693202fd43522229d44f1816bcd96a8a0a7"
    }
  }
]